CRNX
Crinetics Pharmaceuticals Inc
85.00$
+0.0%
vs. previous close
Closing price · As of: Sep 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | – | 100.0% | 100.0% | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 12,670.2% | – | 74.1% | 188.7% | – | – | 0.0% | 93.0% | 63,261.5% | -7.5% | 1.9% | 0.6% | 214.3% | |
| 100.0% | – | 100.0% | 100.0% | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 98.1% | 99.4% | 99.2% | |
| 12,670.2% | – | 8,334.5% | 14,622.6% | – | – | 21,119.1% | 7,788.7% | 63,261.5% | 1,380.5% | 932.4% | 397.5% | 890.6% | |
| 4,475.1% | – | 3,254.4% | 6,225.1% | – | – | 9,841.0% | 4,834.3% | 36,549.0% | 871.6% | 473.6% | 229.2% | 508.5% | |
| 17,145.4% | – | 11,588.9% | 20,847.6% | – | – | 30,960.1% | 12,623.0% | 99,810.5% | 2,269.6% | 1,405.9% | 626.7% | 1,401.7% | |
| -17,045.4% | – | -11,488.9% | -20,747.6% | – | – | -30,860.1% | -12,523.0% | -99,710.5% | -2,169.6% | -1,307.8% | -527.3% | -1,302.5% | |
| -16,606.4% | – | -10,457.8% | -18,560.2% | – | – | -26,807.2% | -11,216.0% | -90,972.7% | -1,990.5% | -1,191.0% | -481.1% | -1,189.5% | |
| -78.9% | – | 0.0% | – | – | – | – | – | – | 2.9% | – | – | – | |
| -16,606.4% | – | -10,457.8% | -18,560.2% | – | – | -26,807.2% | -11,216.0% | -90,972.7% | -1,993.4% | -1,191.0% | -481.1% | -1,189.9% | |
| -16,527.5% | – | -10,383.8% | -18,371.4% | – | – | -26,551.0% | -11,123.0% | -90,265.0% | -1,974.4% | -1,180.2% | -523.1% | -1,206.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.